Penn Study Describes New Models for Testing Parkinson's Disease Immune-based Drugs
Understanding how disease spreads from neuron to neuron is key to finding treatments.
Using powerful, newly developed cell culture and mouse models of sporadic Parkinson's disease (PD), a team of researchers from the Perelman School of Medicine at the University of Pennsylvania, has demonstrated that immunotherapy with specifically targeted antibodies may block the development and spread of PD pathology in the brain. By intercepting the distorted and misfolded alpha-synuclein (a-syn) proteins that enter and propagate in neurons, creating aggregates, the researchers prevented the development of pathology and also reversed some of the effects of already-existing disease. The a-syn clumps, called Lewy bodies, eventually kill affected neurons, which leads to clinical PD.
IOA in the News
Joseph A. Pignolo, Sr. Award in Aging Research
Monday, November 24, 2014
2:30 - 4:00pm | Smilow Center for Translational Research
Keynote Speaker: Dongsheng Cai, MD, PhD - Irma T. Hirschl Scholar; Professor, Department of Molecular Pharmacology, Albert Einstein College of MedicineMore Events
Join the nearly 300 Institute on Aging Fellows and Associate Fellows and experience robust collaborative opportunities in aging at Penn, for funding opportunity alerts, pilot research grant opportunities, and updates on IOA activities.Get Involved
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team